



**Division of Medical Services
Medicaid Pharmacy Program**

P.O. Box 1437, Slot S415, Little Rock, AR 72203-1437
P: 501.683.4120 F: 800-424-5851

October 10, 2025
RE: Updates for Sprycel®

Prescribers and pharmacists,

Sprycel® (dasatinib) tablets have been brand preferred for quite some time. **Effective today**, both the generic (dasatinib) and the brand (Sprycel®) will be available for dispensing to Arkansas Medicaid beneficiaries.

Generic dasatinib tablet will require DAW code of zero (0) to process the payment at the correct generic rate. Sprycel® brand tablet will require a DAW code of nine (9) to ensure the claim is processed as a plan prefers brand (PPB) product and pays at the brand rate. **After 12/01/2025**, brand Sprycel® tablet will no longer be considered the plan preferred brand product while the generic will become the preferred option.

Dasatinib follows our oncology policy and requires prior authorization requests to be submitted.

For your convenience, the oncology policy link and oncology medication PA form have been provided.

https://ar.primetherapeutics.com/documents/d/arkansas/ar_oncology_medication_pa_form-1

https://ar.primetherapeutics.com/documents/d/arkansas/oncology_policy_04172024

For any questions, contact the Prime Therapeutics Help Desk at 800-424-7895.

Sincerely,

Cynthia Neuhofer, Pharm.D.
DMS Assistant Director/Pharmacy Director